Most Read

Merck has announced the first presentation of data from the Phase 3 DRIVE-SHIFT trial evaluating a switch of medication to Delstrigo , a once-daily fixed-dose combination tablet of

In the ongoing study, Biktarvy was found to be statistically non-inferior to a regimen of abacavir/dolutegravir/lamivudine (600/50/300mg, ABC/DTG/3TC) through 96 weeks of therapy. The data will be presented

ALN-AAT02 is Alnylam’s first investigational RNAi therapeutic utilizing the Company’s enhanced stabilization chemistry plus (ESC+) GalNAc-conjugate technology. Alnylam ALN-AAT02 program lead vice president Thomas Hoock said: “We are

Kite and HiFiBiO intend to adapt HiFiBiO’s proprietary single cell technology platform to create a high throughput approach that will potentially allow for the in-depth screening of TCR

Kala Pharmaceuticals chairman, president and CEO Mark Iwicki said: “We are pleased to be partnering with Athyrium and to have their support and confidence in INVELTYS for the

Under the terms of the agreement, Shield will receive an immediate £11 million upfront payment, is eligible to receive up to €4.5m in short-term development milestones and up

Bonti is focused on developing fast-acting neurotoxin programs intended to be used in aesthetic and therapeutic applications. According to the acquisition terms, the Irish drug maker will make

Lumoxiti, which is a CD22-directed cytotoxin, has been approved for the patients who had two or prior systemic therapies, including treatment with a purine nucleoside analog. AstraZeneca executive

VEYVONDI should not be used in the treatment of hemophilia A. VEYVONDI is the first and only recombinant von Willebrand Factor (rVWF) treatment in the EU for von Willebrand disease (VWD)